Valuation : Atossa Therapeutics, Inc.

Market Cap 25.75M 22.24M 20.85M 19.03M 35.79M 2.46B 35.97M 247M 96.46M 1.24B 96.66M 94.56M 4.12B P/E 2026 *
-0.67x
P/E 2027 * -0.82x
Enterprise Value 25.75M 22.24M 20.85M 19.03M 35.79M 2.46B 35.97M 247M 96.46M 1.24B 96.66M 94.56M 4.12B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Atossa Therapeutics, Inc.

1 day-2.27%
1 week+1.57%
Current month+24.64%
1 month+11.69%
3 months-50.67%
6 months-41.76%
Current year-70.85%
1 week 2.45
Extreme 2.45
2.7
1 month 2.05
Extreme 2.05
2.97
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2009
Director of Finance/CFO 50 13/10/2025
Chief Tech/Sci/R&D Officer - 30/09/2025
Director TitleAgeSince
Chairman 75 31/03/2009
Director/Board Member 64 31/03/2009
Director/Board Member 79 30/06/2011
Date Insider Type Main position Quantity % Market Cap.
12/05/26
Ensisheim Partners LLC
OtherCompany 0 0%
12/05/26 Free

Director

10,000 0.1161%
12/05/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-2.27%+1.57%-77.45%-80.17% 25.75M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.61%-0.80%+62.88%+89.83% 27.46B
Weighted average by Cap. -1.70%-1.06%+96.26%+129.01%

Financials

2026 *2027 *
Net sales - -
Net income -34.89M -30.14M -28.26M -25.79M -48.51M -3.33B -48.75M -335M -131M -1.68B -131M -128M -5.59B -38.03M -32.84M -30.79M -28.11M -52.86M -3.63B -53.12M -365M -142M -1.83B -143M -140M -6.09B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
28/08/26 US$2.580 -2.27% 49,003
27/08/26 US$2.640 -0.38% 23,115
26/08/26 US$2.650 -1.12% 26,301
25/08/26 US$2.680 +1.52% 49,690
24/08/26 US$2.640 +3.94% 57,149
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.580USD
Average target price
18.67USD
Spread / Average Target
+623.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock